Axiota Animal Health Names Wamego, Kansas, as Global Headquarters
Move strengthens the KC Animal Health Corridor as a hub for animal health excellence
The announcement formalizes the longstanding presence of Axiota Animal Health in
"
Located near Kansas State University, the facility benefits from proximity to one of the nation's leading veterinary and animal health research institutions. That connection helps Axiota attract specialized scientific talent and collaborate with researchers advancing the future of livestock health.
From its
- Lactipro®, the only rumen-native probiotic that delivers Mega e®, proven to promote rumen health and performance.
- Multimin® 90 (zinc, copper, manganese and selenium injection) is the only FDA-approved injectable supplement that delivers four trace minerals known to support cattle health and reproduction.
The decision highlights the global impact of the KC Animal Health Corridor, a hub stretching from
"Axiota's decision to locate its global headquarters in
About Axiota Animal Health
Axiota Animal Health is an innovation-driven company that discovers, develops and markets products for beef and dairy producers around the world. Axiota's non-antibiotic solutions prepare cattle to thrive during transition and stress and support producers' goals of optimal health, performance and animal well-being. | axiota.com
About KC Animal Health Corridor
Representing more than half of the global animal health industry's sales, and home to over 300 animal health companies, the KC Animal Health Corridor is the largest concentration of its kind worldwide. An initiative of the Kansas City Area Development Council, the Corridor is anchored by
View original content to download multimedia:https://www.prnewswire.com/news-releases/axiota-animal-health-names-wamego-kansas-as-global-headquarters-302730386.html
SOURCE Axiota® Animal Health
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- STEMREGEN® Named to Inc. 5000 for Third Consecutive Year
- Goldcana Announces Closing of Non-Brokered Private Placement Financing for $2 Million
- Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share